Cargando…
Generation of evidence-based carboplatin dosing guidelines for neonates and infants
BACKGROUND: To optimally dose childhood cancer patients it is essential that we apply evidence-based dosing approaches. Carboplatin is commonly dosed to achieve a cumulative target exposure (AUC) in children, with target AUC values of 5.2–7.8 mg/ml.min defined. To achieve these exposures patients ar...
Autores principales: | Barnett, Shelby, Makin, Guy, Tweddle, Deborah A., Osborne, Caroline, Veal, Gareth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10667364/ https://www.ncbi.nlm.nih.gov/pubmed/37816842 http://dx.doi.org/10.1038/s41416-023-02456-y |
Ejemplares similares
-
Vincristine dosing, drug exposure and therapeutic drug monitoring in neonate and infant cancer patients
por: Barnett, Shelby, et al.
Publicado: (2022) -
Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance
por: Nijstad, A. Laura, et al.
Publicado: (2022) -
Carboplatin therapeutic monitoring in preterm and full-term neonates
por: Veal, Gareth J., et al.
Publicado: (2015) -
Pharmacokinetics and Pharmacogenetics of Cyclophosphamide in a Neonate and Infant Childhood Cancer Patient Population
por: Barnett, Shelby, et al.
Publicado: (2021) -
Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens
por: Veal, Gareth J., et al.
Publicado: (2016)